RS56639B1 - Varijante humanog gdnf - Google Patents

Varijante humanog gdnf

Info

Publication number
RS56639B1
RS56639B1 RS20171274A RSP20171274A RS56639B1 RS 56639 B1 RS56639 B1 RS 56639B1 RS 20171274 A RS20171274 A RS 20171274A RS P20171274 A RSP20171274 A RS P20171274A RS 56639 B1 RS56639 B1 RS 56639B1
Authority
RS
Serbia
Prior art keywords
gdnf
variant
human
variants
wild
Prior art date
Application number
RS20171274A
Other languages
English (en)
Serbian (sr)
Inventor
Donmienne Doen Mun Leung
Jirong Lu
Kalpana Mahesh Merchant
Mahmoud Ghanem
Linda Maureen O'bryan
Rosamund Carol Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS56639B1 publication Critical patent/RS56639B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • External Artificial Organs (AREA)
RS20171274A 2011-04-11 2012-04-03 Varijante humanog gdnf RS56639B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf
EP12712874.2A EP2696889B1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (1)

Publication Number Publication Date
RS56639B1 true RS56639B1 (sr) 2018-03-30

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171274A RS56639B1 (sr) 2011-04-11 2012-04-03 Varijante humanog gdnf

Country Status (28)

Country Link
US (1) US9243046B2 (enExample)
EP (1) EP2696889B1 (enExample)
JP (1) JP6093345B2 (enExample)
KR (1) KR101554799B1 (enExample)
CN (1) CN103635201B (enExample)
AU (1) AU2012243178B2 (enExample)
BR (1) BR112013026004B1 (enExample)
CA (1) CA2833158C (enExample)
CY (1) CY1119750T1 (enExample)
DK (1) DK2696889T3 (enExample)
EA (1) EA025129B1 (enExample)
ES (1) ES2656020T3 (enExample)
HR (1) HRP20171993T1 (enExample)
HU (1) HUE036239T2 (enExample)
IL (1) IL228102A (enExample)
LT (1) LT2696889T (enExample)
ME (1) ME02849B (enExample)
MX (1) MX337206B (enExample)
NO (1) NO2696889T3 (enExample)
PL (1) PL2696889T3 (enExample)
PT (1) PT2696889T (enExample)
RS (1) RS56639B1 (enExample)
SG (1) SG193483A1 (enExample)
SI (1) SI2696889T1 (enExample)
TW (1) TWI583698B (enExample)
UA (1) UA112981C2 (enExample)
WO (1) WO2012141936A1 (enExample)
ZA (1) ZA201306556B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3454886A1 (en) 2016-05-13 2019-03-20 Instituto de Medicina Molecular Methods of treating diseases associated with ilc3 cells
US20230022970A1 (en) * 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
EP4347645A1 (en) 2021-06-03 2024-04-10 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Foundation Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
CN116606365A (zh) * 2023-02-24 2023-08-18 肇庆医学高等专科学校 一种gdnf新型变体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) * 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
WO2010090523A1 (en) * 2009-02-06 2010-08-12 Pepscan Systems B.V. Truncated cystine-knot proteins

Also Published As

Publication number Publication date
JP2014512369A (ja) 2014-05-22
NZ614325A (en) 2015-07-31
CN103635201B (zh) 2016-11-09
AU2012243178B2 (en) 2016-09-29
SI2696889T1 (en) 2018-01-31
EP2696889B1 (en) 2017-11-15
EP2696889A1 (en) 2014-02-19
CY1119750T1 (el) 2018-06-27
JP6093345B2 (ja) 2017-03-08
CN103635201A (zh) 2014-03-12
US9243046B2 (en) 2016-01-26
BR112013026004A2 (pt) 2016-11-29
DK2696889T3 (en) 2018-01-22
KR101554799B1 (ko) 2015-09-21
PL2696889T3 (pl) 2018-04-30
US20130324474A1 (en) 2013-12-05
MX2013011919A (es) 2014-03-27
CA2833158A1 (en) 2012-10-18
ZA201306556B (en) 2015-03-25
IL228102A (en) 2017-04-30
ES2656020T3 (es) 2018-02-22
HUE036239T2 (hu) 2018-06-28
TW201245220A (en) 2012-11-16
ME02849B (me) 2018-01-20
HRP20171993T1 (hr) 2018-02-09
UA112981C2 (uk) 2016-11-25
BR112013026004B1 (pt) 2020-09-29
PT2696889T (pt) 2018-02-05
LT2696889T (lt) 2018-02-12
KR20130131470A (ko) 2013-12-03
EA201370204A1 (ru) 2014-02-28
MX337206B (es) 2016-02-17
SG193483A1 (en) 2013-10-30
WO2012141936A1 (en) 2012-10-18
IL228102A0 (en) 2013-09-30
NO2696889T3 (enExample) 2018-04-14
AU2012243178A1 (en) 2013-09-05
TWI583698B (zh) 2017-05-21
EA025129B1 (ru) 2016-11-30
CA2833158C (en) 2018-07-17

Similar Documents

Publication Publication Date Title
US8309068B2 (en) Isolated polypeptides and methods of improving muscle strength
UA74146C2 (uk) Модифікований хімеричний поліпептид з покращеними фармакокінетичними властивостями
IE921654A1 (en) Structure, production and use of heregulin
EP3052519B1 (en) Protoxin-ii variants and methods of use
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
WO2016140859A2 (en) Protoxin-ii variants and methods of use
AU2016242905A1 (en) Protoxin-II variants and methods of use
US9243046B2 (en) Variants of human GDNF
WO2009116639A1 (ja) ラクリチンの部分ペプチド
WO2012038953A2 (en) Fgf-18 truncated variants having increased receptor specificity and uses thereof
NZ614325B2 (en) Variants of human gdnf
HK1190308B (en) Variants of human gdnf
HK1190308A (en) Variants of human gdnf
AU2013231037B2 (en) Myostatin antagonists
JP2002335972A (ja) インスリン受容体関連受容体結合蛋白質及びその利用